Phase 3 Canines Lymphoma B Trial ( what to expect), page-69

First 69 Last

Share
Profile

Follow
Peeteepoo

2,675 Posts.

1603

29/11/21

11:52

Post #: 57930801
Share

Originally posted by kpax: ↑

Hello All,

Looks like we have competition on our oral Lymphoma B drug for doggie Cancer.

The FDA have approved Laverdia-Ca1 which is owned by a private Company Anivive Life science. This approval was after completion of a Phase 3 trial with 58 dogs. This is the first oral Lymphoma B drug given clearance.

Results were varied but well within our anticipated projections. So that part is achievable to exceed their results.

They were in brief. 29% of dogs didn't have progression of the disease for 56 days. 7% of dogs did not have disease progression for 182 days.

Costings : 41 kg dog $ 176 USD per week. 21 kg dog $ 36 USD per week..11 kg dog $ 22 USD per week.

Doseage is twice per week.

The down side is significant side effects. Including you should not have any of the dogs bodily fluids on oneself. Wearing chemotherapy gloves to dispose of their waste. Nausea, vomiting, diarrhoea, anorexia, increased thirst, increased urine output and lethargy increased liver enzymes.

Ok, so how does it work. The drug prevents certain cells to leave the nucleus of the cancer cells to stop replication.

The comparison. Monepantel has achieved a median survival time of 138 days. Greater than 70% of dogs have stable disease. Monepantel has achieved reduction in tumour sizes up to 19%. Monepantel administration achieves dogs to have a high quality of life. I am sure there is more. But, I will let you tell us more.

I have mentioned before of our strategy. Considered, that we do have minor side effects, there is a possibility of placing our dogs on Maxalon a very cheap effective anti nausea treatment that will allieviate most of our minor side effects. Giving an even greater quality of life.

The upside of this , is that we know the minimum amount of dogs we need to satisfy the FDA. Secondly, we have tweaked dose age from Phase 2 and 2b trials. Thirdly, we are using a combination drug to improve the synergy of Monepantel. Fourthly our beloved dogs are not toxic during their treatment.

Onwards and upwards HC members.

( Havenots, I have not forgotten to answer the Omicron v Delta v Alpha RNA strain question, will do soon )

Expand

Thanks Kpax,
Based on a P3 of 53 dogs. I will take that as a tick for Monepantel, and will make a great bargaining point in negotiations as we now have a benchmark of what will be needed to gain FDA approval.

Pete

PAA Price at posting: 9.5¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

What's causing the cost-of-living crisis, and how to navigate it

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon